1page img1 jpg
Gamma Vaccines’ lead product is GammaFlu® that offers broader spectrum immunity to different influenza viruses. Gamma Vaccines technology has the potential to create improved seasonal flu vaccines for human use as well more effective flu vaccines for protecting poultry and pigs from avian and swine flu strains. The Company has an innovative pipeline of additional gamma-irradiated vaccines that provide protection against other important human and veterinary pathogens.
Gamma Vaccines manufactures and kills influenza virus in a manner that preserves the proper structure of the virus and its various proteins. By using gamma irradiation – a procedure in wide-spread use to sterilize surgical instruments and stop spoilage of perishable fruits – a killed virus preparation can be obtained that is no longer infectious and which induces a potent immunity to different influenza virus strains and subtypes.

About

Gamma Vaccines Pty Ltd is an Australian company targeting primarily the human and avian influenza market.

Formed in July 2009, the company is developing a cross-protective influenza virus vaccine, GammaFlu®, designed to replace current seasonal injectable flu vaccines with an easy-to-administer, broader-spectrum intranasal vaccine. The Company’s products also hold the prospect of being able to be stockpiled for use as an immediate first response to any new influenza pandemic. In addition, Gamma Vaccines is developing a vaccine that can provide better protection against highly pathogenic avian influenza in poultry. The Company is also conducting research on vaccines for preventing bacterial pneumonia.

Gamma Vaccines’ proprietary technology was invented by leading researchers from The Australian National University’s John Curtin School of Medical Research and The University of Adelaide’s School of Molecular Life Sciences. The company has attracted significant equity investments from Australian, Indonesian & US investors and been awarded numerous grants from the Australian Capital Territory and the Commonwealth Government of Australia.

Founded by experienced early-stage managers and the inventors themselves, the company is currently negotiating with several partners in Asia and Europe to commence clinical trials for applications in both human and animal vaccination markets.

Recent News

  • New Director Appointed | 1 June 2017GAMMA VACCINES APPOINTS MR HUGH CRAWFORD AS A NON-EXECUTIVE DIRECTOR
  • Director Retires | 24 May 2017DR JEAN PETRE HAS RETIRED AS A DIRECTOR OF GAMMA VACCINES AFTER 6 YEARS OF SERVICE WHICH THE COMPANY GRATEFULLY ACKNOWLEDGES
  • Publication in Vaccine | 15 February 2017PUBLICATION IN VACCINE OF A STUDY ON THE IMPACT OF GAMMA IRRADIATION ON THE IMMUNOGENICITY OF INACTIVATED INFLUENZA VACCINES
  • Patent Granted in South Korea | 10 February 2017GAMMA VACCINES CORE INTELLECTUAL PROPERTY ON INFLUENZA VACCINES GRANTED IN SOUTH KOREA
  • Publication in Clinical Science | 23 December 2016PUBLICATION IN CLINICAL SCIENCE OF GAMMA VACCINES’ BROAD-SPECTRUM COMBINATION VACCINE AGAINST PNEUMOCOCCAL PNEUMONIA AND INFLUENZA [Download]
Read More
 

Gamma Vaccines Pty Ltd © 2010 - 2017. Privacy Policy | Designed by GreenDot Pty Ltd & Clearpath |Sitemap